exatecan mesylate
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia
Conditions
Leukemia, Myelodysplastic Syndromes
Trial Timeline
Jun 1, 1999 → Apr 1, 2005
NCT ID
NCT00004047About exatecan mesylate
exatecan mesylate is a phase 1 stage product being developed by Daiichi Sankyo for Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00004047. Target conditions include Leukemia, Myelodysplastic Syndromes.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00055952 | Phase 2 | Completed |
| NCT00055939 | Phase 2 | Completed |
| NCT00017212 | Phase 2 | Completed |
| NCT00005938 | Phase 2 | Completed |
| NCT00004866 | Phase 2 | Completed |
| NCT00004108 | Phase 2 | Completed |
| NCT00004060 | Phase 2 | Completed |
| NCT00004046 | Phase 2 | Completed |
| NCT00003951 | Phase 2 | Completed |
| NCT00004045 | Phase 2 | Completed |
| NCT00004047 | Phase 1 | Completed |
Competing Products
20 competing products in Leukemia